Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Details
Original language | English |
---|---|
Journal | The Lancet Neurology |
Publication status | Published - 2018 |
Peer-reviewed | Yes |
External IDs
Scopus | 85043460798 |
---|